| Literature DB >> 36070997 |
Abstract
Cancer rehabilitation aims to enable patients to maximize their physical, social, psychological, and vocational functions within the limits that arise during the course of the disease and its treatment. According to recent domestic studies, most patients report one or more physical problems during or after cancer treatment. This review presents the latest updates on cancer-related rehabilitation issues. Cancer rehabilitation in Korea still faces various barriers, including a lack of awareness, problems with the healthcare delivery system, and high costs, and recognizing the need for rehabilitation during cancer treatment varies among patients and even physicians. Hence, an appropriate cooperative referral system for cancer rehabilitation requires improvement. We herein review the current status of and barriers to cancer rehabilitation in South Korea to resolve the issues of domestic cancer rehabilitation.Entities:
Keywords: Cancer; Rehabilitation; Statistics
Year: 2022 PMID: 36070997 PMCID: PMC9452290 DOI: 10.5535/arm.22102
Source DB: PubMed Journal: Ann Rehabil Med ISSN: 2234-0645
Crude and age-standardized cancer incidence rates by sex in Korea, 2019
| Ranking | Site/type | Number of patients (/100,000) | Fraction (%) | Crude incidence rates (/100,000) | Standardized incidence rates (/100,000) |
|---|---|---|---|---|---|
| All type | 254,718 | 100.0 | 496.2 | 295.8 | |
| 1 | Thyroid | 30,676 | 12.0 | 59.8 | 52.3 |
| 2 | Lung | 29,960 | 11.8 | 58.4 | 28.2 |
| 3 | Stomach | 29,493 | 11.6 | 57.4 | 30.8 |
| 4 | Colon | 29,030 | 11.4 | 56.5 | 30.0 |
| 5 | Breast | 24,933 | 9.8 | 48.6 | 34.3 |
| 6 | Prostate | 16,803 | 6.6 | 32.7 | 15.5 |
| 7 | Liver | 15,605 | 6.1 | 30.4 | 16.1 |
| 8 | Pancreas | 8,099 | 3.2 | 15.8 | 7.8 |
| 9 | Gallbladder | 7,383 | 2.9 | 14.4 | 6.6 |
| 10 | Kidney | 6,026 | 2.4 | 11.7 | 7.4 |
Adapted from the National Cancer Information Center (https://www.cancer.go.kr).
Fig. 1Unmet needs (experience of rehabilitation/demand for rehabilitation) of patients with actual rehabilitation problems. Adapted from Jo et al. J Korean Acad Rehabil Med 2010;34:691–700 [5].
Chemotherapeutic agents that cause peripheral neuropathies and associated features
| Type | Threshold dose | Sensory neuropathy | Motor neuropathy | Autonomic neuropathy | Other characteristics |
|---|---|---|---|---|---|
| Oxaliplatin | >550 mg/m2 | Acute sensory symptoms, chronic sensory neuropathy | Acute cramps and fasciculation | Rare | Cold-induced dysesthesia |
| Cisplatin | >350 mg/m2 | Predominant sensory neuropathy | Rare | Rare | Coasting phenomenon |
| Vincristine | >2–6 mg/m2 | Sensory neuropathy | Muscle cramps and mild distal weakness | Yes | Coasting phenomenon |
| Paclitaxel | >300 mg/m2 | Predominant sensory neuropathy | Myalgia and myopathy | Rare | - |
| Docetaxel | >100 mg/m2 | Predominant sensory neuropathy | Myalgia and myopathy | Yes | - |
| Thalidomide | >20 g | Sensory neuropathy | Mild distal weakness and cramps | Rare | - |
| Bortezomib | >16 mg/m2 | Painful, small-fiber sensory neuropathy | Rare | Rare | Favorable outcome with dose reduction or cessation |